ArticleJCI insight2016
Lymphocyte activation gene 3 and coronary artery disease.
Open access · goldAbstract read
In one paragraph
Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 50 citations in OpenAlex.
- High-density lipoprotein cholesterol: function, dysfunction, and clinical implications.American journal of preventive cardiology · 2026Article
- The Relationship and Mechanism of CD27 with Coronary Atherosclerotic Heart Disease.Cardiovascular drugs and therapy · 2026Review
- Review
- Anti PD-L1 immunotherapy alters macrophage phenotypes via EGR1 and HSP90AB1 supported by integrated methodologies.Scientific reports · 2025Article
- Positron Emission Tomography Imaging of the Adaptive Immune System in Cardiovascular Diseases.Chemical & biomedical imaging · 2025Review
- The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure.Frontiers in immunology · 2025Review
- The impact of immune checkpoint inhibition on atherosclerosis in cancer patients.Frontiers in immunology · 2025Review
- Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy.Cellular and molecular life sciences : CMLS · 2024Review
- Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall.International journal of molecular sciences · 2024Review
- Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.Frontiers in immunology · 2024Review
- Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study.Frontiers in pharmacology · 2024Article
- Higher HDL cholesterol levels are associated with increased markers of interstitial myocardial fibrosis in the MultiEthnic Study of Atherosclerosis (MESA).Scientific reports · 2023Article
- Advances in immune checkpoint-based immunotherapies for multiple sclerosis: rationale and practice.Cell communication and signaling : CCS · 2023Review
- Article
- LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice.JACC. CardioOncology · 2022Article
- Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management:JACC. CardioOncology · 2022Review
- TACE/ADAM17 substrates associate with ACS (Ep-CAM, HB-EGF) and follow-up MACE (TNFR1 and TNFR2).Atherosclerosis plus · 2022Article
- Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor.Cells · 2022Review
- Lymphocyte activation gene-3-associated protein networks are associated with HDL-cholesterol and mortality in the Trans-omics for Precision Medicine program.Communications biology · 2022Article
- Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Diana GoldenCenter for Vascular Biology and.
Antonina KolmakovaCenter for Vascular Biology and.
Sunitha SuraCenter for Vascular Biology and.
Anthony T VellaDepartment of Immunology, University of Connecticut Health Center, Farmington, Connecticut, USA.
Ani ManichaikulCenter for Public Health Genomics, University of Virginia, Charlottesville, Virginia.
Xin-Qun WangBiostatistics Section, Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA.
Suzette J BielinskiDivision of Epidemiology, Mayo Clinic, Rochester, Minnesota, USA.
Kent D TaylorLos Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, California, USA.
Yii-Der Ida ChenLos Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, California, USA.
Stephen S RichCenter for Public Health Genomics, University of Virginia, Charlottesville, Virginia.
Annabelle RodriguezCenter for Vascular Biology and.
Center for Vascular Biology Research · USUniversity of Virginia · USCancer Research And Biostatistics · USMayo Clinic · USUConn Health · US
Funding
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0MTransgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PETER J TONTONOZ · 2003 to 2026
$40.4MProject 5: ROS, Glutathione and Vascular Response to Diesel ExhaustP50ES015915 · NIEHS · UNIVERSITY OF WASHINGTON · PI KAUFMAN, JOEL DANIEL · 2008 to 2012
$11.8MThe Role of Scavenger Receptor Class B Type 1 in HumansR01HL075646 · NHLBI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI RODRIGUEZ, ANNABELLE · 2004 to 2013
$4.5MLympocyte Activation Gene-3 Deficiency Linked to Proinflammation and AtherosclerosisR01HL131862 · NHLBI · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI RODRIGUEZ, ANNABELLE · 2016 to 2019
$3.0MNCATS NIH HHS UL1 TR000124NHLBI NIH HHS R01 HL075646NHLBI NIH HHS R01 HL131862NIDDK NIH HHS P30 DK063491NIEHS NIH HHS P50 ES015915NIH HHS HHSN263201500003I
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdolescentAdultAgedAged, 80 and overAntigens, CDAtherosclerosisCholesterol, HDLCoronary Artery DiseaseFemaleHumansLymphocyte Activation Gene 3 ProteinMaleMembrane MicrodomainsMiddle AgedScavenger Receptors, Class BYoung AdultAntigens, CDCholesterol, HDLLag3 protein, humanLymphocyte Activation Gene 3 ProteinSCARB1 protein, humanScavenger Receptors, Class B
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.